MedTrace Logo

DLCS for Predicting Neoadjuvant Chemotherapy Response

NCT05617469 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2022-11-15

No results posted yet for this study

Summary

The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.

Conditions

  • Gastric Cancer
  • CT Images
  • Deep Learning
  • Neoadjuvant Chemotherapy
  • Tumor Regression Grade

Interventions

OTHER

develop and visualized a radio-clinical signatures from pretreatment oversampled CT images

develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-01-30
Completion
2023-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05617469 on ClinicalTrials.gov